Cargando…
Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is a common subtype of non-Hodgkin's lymphoma and is very likely to infiltrate the bone marrow. Over 30% of patients are converted to relapsed/refractory DLBCL after first-line rituximab combined with cyclophosphamide, doxorubicin,...
Autores principales: | Wang, Di, Liu, Peng, Zhang, Yue, Liu, Hui-Ying, Shen, Di, Che, Yi-Qun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252218/ https://www.ncbi.nlm.nih.gov/pubmed/30534553 http://dx.doi.org/10.1155/2018/1042597 |
Ejemplares similares
-
Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014) -
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020) -
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021) -
Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)